Back to search
Malignant Rhabdoid Tumors (MRT)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Malignant Rhabdoid Tumors (MRT) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Malignant Rhabdoid Tumors (MRT) trials you may qualify forThis research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor,…
This study incorporates alisertib, the small-molecule inhibitor of Aurora A activity, in the treatment of patients younger than 22 years of age. Patients with r…
This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include f…
This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating patients with osteosarcoma, malignant rhabdoid tumor/atypical tera…
LEE011 is a small molecule inhibitor of CDK4/6. LEE011 has demonstrated in vitro and in vivo activity in both tumor models. The primary purpose of this study wa…
This research trial studies biomarkers in samples from patients with rhabdoid tumor of the kidney and atypical teratoid rhabdoid tumor. Studying biomarkers of t…